- Home
- TNYA vs NRO Comparison
TNYA vs NRO Comparison
Compare TNYA & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- NRO
- Stock Information
- Founded
- TNYA 2016
- NRO 2003
- Country
- TNYA United States
- NRO United States
- Employees
- TNYA N/A
- NRO N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- NRO Finance/Investors Services
- Sector
- TNYA Health Care
- NRO Finance
- Exchange
- TNYA Nasdaq
- NRO Nasdaq
- Market Cap
- TNYA 189.1M
- NRO 203.4M
- IPO Year
- TNYA 2021
- NRO N/A
- Fundamental
- Price
- TNYA $2.13
- NRO $3.15
- Analyst Decision
- TNYA Strong Buy
- NRO
- Analyst Count
- TNYA 5
- NRO 0
- Target Price
- TNYA $8.60
- NRO N/A
- AVG Volume (30 Days)
- TNYA 3.9M
- NRO 239.4K
- Earning Date
- TNYA 11-05-2025
- NRO 01-01-0001
- Dividend Yield
- TNYA N/A
- NRO 11.41%
- EPS Growth
- TNYA N/A
- NRO N/A
- EPS
- TNYA N/A
- NRO N/A
- Revenue
- TNYA N/A
- NRO N/A
- Revenue This Year
- TNYA N/A
- NRO N/A
- Revenue Next Year
- TNYA N/A
- NRO N/A
- P/E Ratio
- TNYA N/A
- NRO N/A
- Revenue Growth
- TNYA N/A
- NRO N/A
- 52 Week Low
- TNYA $0.36
- NRO $2.51
- 52 Week High
- TNYA $4.01
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- TNYA 77.99
- NRO 36.63
- Support Level
- TNYA $1.59
- NRO $3.19
- Resistance Level
- TNYA $1.72
- NRO $3.25
- Average True Range (ATR)
- TNYA 0.15
- NRO 0.04
- MACD
- TNYA 0.04
- NRO -0.01
- Stochastic Oscillator
- TNYA 77.18
- NRO 0.00
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").